

Atezolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung

Daratumumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Filgrastim

Section	Indications
Immunomodulators Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	Plasma cell myeloma

Nivolumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung Melanoma of skin

Pembrolizumab

Section	Indications
Immunomodulators	Therapeutic equivalent to nivolumab for Melanoma of skin

Thalidomide

Section

Immunomodulators

Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tislelizumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma